CLINICAL STUDY Three-month sustained-release triptorelin (11.25mg) in the treatment of central precocious puberty

*Members are listed in the acknowledgements section Objective: Depot GnRH agonists are commonly used in the treatment of central precocious puberty (CPP). The triptorelin 11.25 mg 3-month depot, currently used in adult indications, had not pre-viously been evaluated in CPP. Design: This was a multicenter, open-label, 12 month trial conducted in 64 CPP children (54 girls and 10 boys), treated quarterly. Methods: Children with a clinical onset of pubertal development before the age of 8 years (girls) or 9 years (boys), pubertal response of LH to GnRH $7 IU/l, advanced bone age.1 year, enlarged uterus ($36 mm) and testosterone level $0.5 ng/ml (boys), were included. Suppression of gonadotropic activation, as determined from serum LH, FSH, estradiol or testosterone, and pubertal signs were assessed at Months 3, 6 and 12. Results: GnRH-stimulated peak LH #3 IU/l, the main efficacy criterion, was met in 53 out of 6